AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28739794 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 60
Study 28739794 — intervention group
Group type: COMPARATOR
Intervention: Sutezolid
Number of subjects: 60
Study 26276704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Parental Coaching (IPC)
Number of subjects: 45
Study 26276704 — intervention group
Group type: COMPARATOR
Intervention: Standard Family-Based Treatment (FBT)
Number of subjects: 45
Study 23695207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet with weekly group support and work cafeteria options for 18 weeks
Number of subjects: 100
Study 23695207 — intervention group
Group type: COMPARATOR
Intervention: No diet changes for 18 weeks
Number of subjects: 100
Study 21145112 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (Problem Solving Treatment and exposure) for 6 weeks
Number of subjects: 120
Study 21145112 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 120
Study 18804343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth section technique used
Number of subjects: 25
Study 18804343 — intervention group
Group type: COMPARATOR
Intervention: No tooth section technique used (Control)
Number of subjects: 25
Study 17075089 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing wedge technique
Number of subjects: 92
Study 17075089 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening wedge technique
Number of subjects: 92
Study 17075089 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 92
Study 12667723 — intervention group
Group type: EXPERIMENTAL
Intervention: apomorphine SL
Number of subjects: 12
Study 12667723 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10889113 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (14.4 Gy, 1.8 Gy per day, five fractions per week)
Number of subjects: 40
Study 8769361 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 40 mg sublingually twice daily for 8 weeks
Number of subjects: 13
Study 8769361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1555628 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of 1.5 MU of streptokinase
Number of subjects: 38
Study 1555628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 4002782 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg muzolimine
Number of subjects: 2
Study 4002782 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene
Number of subjects: 2
Study 30065082 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas mask
Number of subjects: 14
Study 30065082 — intervention group
Group type: COMPARATOR
Intervention: No gas mask
Number of subjects: 14
Study 27797291 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1905
Study 27797291 — intervention group
Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 1905
Study 24876771 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSMP plus supervised exercise
Number of subjects: 84
Study 24876771 — intervention group
Group type: COMPARATOR
Intervention: CDSMP alone (control)
Number of subjects: 84
Study 22051247 — intervention group
Group type: EXPERIMENTAL
Intervention: Allevyn™ (polyurethane dressing)
Number of subjects: 36
Study 22051247 — intervention group
Group type: COMPARATOR
Intervention: Kaltostat® (calcium alginate dressing)
Number of subjects: 36
Study 20204944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (COG) writing
Number of subjects: 130
Study 20204944 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional disclosure (ED)
Number of subjects: 130
Study 20204944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of emotional disclosure and cognitive reappraisal (ED and COG)
Number of subjects: 130
Study 20204944 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study 18831745 — intervention group
Group type: EXPERIMENTAL
Intervention: OAK program (education self-management program for OA of the knee)
Number of subjects: 146
Study 18831745 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management (control group)
Number of subjects: 146
Study 16444855 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of L-arginine daily
Number of subjects: 80
Study 16444855 — intervention group
Group type: COMPARATOR
Intervention: 0 g of L-arginine daily (Control)
Number of subjects: 80
Study 16444855 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of L-arginine daily
Number of subjects: 80
Study 16444855 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of L-arginine daily
Number of subjects: 80
Study 12131067 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 6
Study 12131067 — intervention group
Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 6
Study 10534332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality trials investigating portal hypertension
Number of subjects: 235
Study 10534332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality trials that are multicentered
Number of subjects: 235
Study 10534332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality trials sponsored by public organizations
Number of subjects: 235
Study 10534332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality trials sponsored by the drug and device industry
Number of subjects: 235
Study 7494013 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN anaerobic bottles
Number of subjects: 694
Study 7494013 — intervention group
Group type: COMPARATOR
Intervention: Standard anaerobic bottles
Number of subjects: 694
Study 1955631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 1
Study 1955631 — intervention group
Group type: COMPARATOR
Intervention: Brazil ginseng dust exposure
Number of subjects: 1
Study 1955631 — intervention group
Group type: COMPARATOR
Intervention: Korean ginseng (Panax ginseng)
Number of subjects: 1
Study 6961468 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid in the form of evening primrose oil (Efamol)
Number of subjects: 50
Study 6961468 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 30657996 — intervention group
Group type: EXPERIMENTAL
Intervention: CL-108 (Hydrocodone 7.5 mg/Acetaminophen 325 mg/Rapid-Release, Low-Dose Promethazine 12.5 mg)
Number of subjects: 466
Study 30657996 — intervention group
Group type: EXPERIMENTAL
Intervention: CL-108
Number of subjects: 466
Study 30657996 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone 7.5 mg/Acetaminophen 325 mg (HC/APAP)
Number of subjects: 466
Study 30657996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 30400898 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing (oral testing)
Number of subjects: 150
Study 30400898 — intervention group
Group type: COMPARATOR
Intervention: Provider administered test (finger-prick testing)
Number of subjects: 150
Study 30400898 — intervention group
Group type: COMPARATOR
Intervention: Provider administered test (in-person counselling)
Number of subjects: 150
Study 27085261 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational web page
Number of subjects: 96
Study 27085261 — intervention group
Group type: COMPARATOR
Intervention: Wait 30 minutes (Control)
Number of subjects: 96
Study 27085261 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-experienced cohort
Number of subjects: 96
Study 25198108 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study 25198108 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 36
Study 22225858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 22225858 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 22225858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with concomitant use of platelet function inhibitors/acetylsalicylic acid
Number of subjects: 0
Study 22225858 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin with concomitant use of platelet function inhibitors/acetylsalicylic acid
Number of subjects: 0
Study 20361031 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy
Number of subjects: 1541
Study 17924895 — intervention group
Group type: EXPERIMENTAL
Intervention: Biovalve PUR cannula
Number of subjects: 70
Study 17924895 — intervention group
Group type: COMPARATOR
Intervention: Vialon cannula
Number of subjects: 70
Study 15834592 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg with 1,000 mg calcium and 800 IU vitamin D daily
Number of subjects: 120
Study 15834592 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg calcium and 800 IU vitamin D daily
Number of subjects: 120
Study 11902616 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of individual mobility ideology by low-status group members
Number of subjects: 3
Study 11902616 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of individual mobility ideology by high-status group members
Number of subjects: 3
Study 10089855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing therapy
Number of subjects: 42
Study 10089855 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 42
Study 8574724 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 16
Study 8574724 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.150 mg)
Number of subjects: 16
Study 2297502 — intervention group
Group type: EXPERIMENTAL
Intervention: DNCB applied to an area of less than 1 cm2
Number of subjects: 0
Study 2297502 — intervention group
Group type: COMPARATOR
Intervention: DNCB applied to larger areas
Number of subjects: 0
Study 2297502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the concentration of DNCB while keeping the area constant
Number of subjects: 0
Study 876327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early systemic chemotherapy (5‐fluorouracil, cyclophosphamide and prednisone)
Number of subjects: 75
Study 876327 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment upon appearance of progressive metastatic disease
Number of subjects: 75
Study 876327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group (excluding early progression)
Number of subjects: 75
Study 876327 — intervention group
Group type: COMPARATOR
Intervention: Control group (excluding early progression)
Number of subjects: 75
Study 876327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 75
Study 876327 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 876327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progression group
Number of subjects: 75
Study 31402735 — intervention group
Group type: EXPERIMENTAL
Intervention: PPROM
Number of subjects: 1729
Study 31402735 — intervention group
Group type: COMPARATOR
Intervention: sPTL
Number of subjects: 1729
Study 31082947 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge fenestrated IV catheter (group 2)
Number of subjects: 300
Study 31082947 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge fenestrated IV catheter (group 3)
Number of subjects: 300
Study 31082947 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge nonfenestrated conventional IV catheter (group 1)
Number of subjects: 300
Study 28587203 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (520 mg of DHA + EPA-enriched fish-oil daily)
Number of subjects: 54
Study 28587203 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 54
Study 26158889 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet Therapy (IT)
Number of subjects: 116
Study 26158889 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 116
Study 26158889 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 116
Study 24479211 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% maleic acid
Number of subjects: 20
Study 24479211 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 20
Study 24479211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite followed by 7% maleic acid
Number of subjects: 20
Study 24479211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite followed by 17% EDTA
Number of subjects: 20
Study 24479211 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 21647905 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKnife tonsillectomy (PKT)
Number of subjects: 32
Study 21647905 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cautery tonsillectomy (MCT)
Number of subjects: 32
Study 19602503 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h on-call duty (OCD)
Number of subjects: 30
Study 16482367 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Index Score (RISc) algorithm
Number of subjects: 2576
Study 16482367 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical validation of RISc
Number of subjects: 2576
Study 14629081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered interdisciplinary team intervention designed to improve transitions across sites of geriatric care
Number of subjects: 0
Study 11898712 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions
Number of subjects: 0
Study 11898712 — intervention group
Group type: COMPARATOR
Intervention: Traditional methodologies
Number of subjects: 0
Study 9699418 — intervention group
Group type: EXPERIMENTAL
Intervention: MND ANA immunofluorescence pattern
Number of subjects: 21
Study 9699418 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity purified anti-70 kDa
Number of subjects: 21
Study 8018456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 8
Study 8018456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8018456 — intervention group
Group type: COMPARATOR
Intervention: Dopamine infusion (3 micrograms kg‐1 min‐1) with placebo
Number of subjects: 8
Study 8018456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3 micrograms kg‐1 min‐1) with metoprolol
Number of subjects: 8
Study 2588205 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhaler alone
Number of subjects: 10
Study 2588205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (slow inhaled flow rate, about 25 l/min)
Number of subjects: 10
Study 2588205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (fast inhaled flow rate, about 100 l/min)
Number of subjects: 10
Study 2588205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (slow inhaled flow rate)
Number of subjects: 10
Study 2588205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer
Number of subjects: 10
Study 796943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily in three divided doses of 50 mg)
Number of subjects: 9
Study 796943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31428908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or the combination with chemotherapy
Number of subjects: 271
Study 31428908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-containing regimens
Number of subjects: 271
Study 31428908 — intervention group
Group type: COMPARATOR
Intervention: Dual HER2-targeted therapy versus trastuzumab
Number of subjects: 271
Study 31428908 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2E tumors
Number of subjects: 271
Study 31428908 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ESR1 gene expression
Number of subjects: 271
Study 31428908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype
Number of subjects: 271
Study 28362143 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot centered position with hands free
Number of subjects: 25
Study 28362143 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe fixed position with hands on hips
Number of subjects: 25
Study 28362143 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-heel changing position with hands on hips
Number of subjects: 25
Study 28362143 — intervention group
Group type: EXPERIMENTAL
Intervention: Any combination of foot alignments and/or hand constraints
Number of subjects: 25
Study 26298020 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace with unrestricted ROM
Number of subjects: 70
Study 26298020 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace fixed at 15° plantar flexion
Number of subjects: 70
Study 26298020 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace restricted with 15°/50° dorsal/plantar flexion
Number of subjects: 70
Study 26298020 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace for ligament instabilities
Number of subjects: 70
Study 26298020 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic ankle bandage
Number of subjects: 70
Study 26298020 — intervention group
Group type: COMPARATOR
Intervention: Control group (without a brace)
Number of subjects: 70
Study 23123382 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 200
Study 23123382 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (control)
Number of subjects: 200
Study 21752826 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 23
Study 21752826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19527449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aironet educational program (received at baseline and 2 months later)
Number of subjects: 123
Study 19527449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 123
Study 19527449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aironet educational program
Number of subjects: 123
Study 16643703 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-before-threat leaflet
Number of subjects: 178
Study 16643703 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-before-efficacy leaflet
Number of subjects: 178
Study 16643703 — intervention group
Group type: COMPARATOR
Intervention: No leaflet (control)
Number of subjects: 178
Study 14985220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 2 weeks)
Number of subjects: 56
Study 14985220 — intervention group
Group type: COMPARATOR
Intervention: Control (multivitamin alone)
Number of subjects: 56
Study 11341459 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 18
Study 11341459 — intervention group
Group type: COMPARATOR
Intervention: No treatment after trial
Number of subjects: 18
Study 9145841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg every 12 h for 2 weeks
Number of subjects: 64
Study 9145841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg every 12 h for 2 weeks
Number of subjects: 64
Study 9145841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg every 12 h for 2 weeks
Number of subjects: 64
Study 9145841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 500 mg every 12 h for 2 weeks
Number of subjects: 64
Study 9145841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tool
Number of subjects: 50
Study 29114896 — intervention group
Group type: COMPARATOR
Intervention: Control (no shared decision-making tool)
Number of subjects: 50
Study 27401788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d for 12 weeks
Number of subjects: 71
Study 27401788 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 71
Study 24738701 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 44
Study 24738701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23733798 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zinc orally every day for 2 weeks
Number of subjects: 272
Study 23733798 — intervention group
Group type: COMPARATOR
Intervention: Placebo suspension orally every day for 2 weeks
Number of subjects: 272
Study 19266828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) as preinduction over 15 min and 0.2‐1 microg kg(‐1) hr(‐1) by continuous i.v. infusion during operation
Number of subjects: 50
Study 19266828 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1 microg kg(‐1) as induction i.v. over 15 min and 0.05‐1 microg kg(‐1) min(‐1) as maintenance
Number of subjects: 50
Study 17290160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (60 mg daily for 3 months)
Number of subjects: 60
Study 17290160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15326072 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 960
Study 15326072 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 960
Study 11802818 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different road safety interventions: 1) three-dimensional model of the traffic environment; 2) road safety board game; 3) illustrated posters and flip-chart materials.
Number of subjects: 120
Study 11802818 — intervention group
Group type: EXPERIMENTAL
Intervention: Training from the road safety interventions
Number of subjects: 120
Study 11802818 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who did not receive the interventions)
Number of subjects: 120
Study 9723661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 17
Study 9723661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8036464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II fecal occult blood testing (performed on 3 days and repeated after 16 to 24 months)
Number of subjects: 68308